Skip to main content
← All research

U.S. Pharma Manufacturing and R&D Site Investments Announced in 2025 and 2026

U.S. Pharma Manufacturing and R&D Site Investments Announced in 2025 and 2026

Pharma companies named 52 new or expanded US manufacturing and R&D sites between January 2025 and November 2026, with $66.1B in disclosed site-level investment, and Eli Lilly accounts for $25.5B of that total across 5 sites. The site announcements sit inside much larger company-level commitments, which add up to about $600B across 16 companies, although those pledges cover different periods and include R&D spending.

This review maps where the named sites are, what they will make, and how tariff and pricing policy shaped the timing of the announcements.

Bar chart of disclosed US manufacturing and R&D site investments by company, announced January 2025 to November 2026, with the number of named sites. Eli Lilly accounts for $25.5B of $66.1B.

Where the sites are

California and North Carolina lead with 7 named projects each, followed by Indiana (5), Texas (4), and Pennsylvania (4), and Virginia, Maryland, Massachusetts, and Illinois have 3 each. The 52 projects span 20 states, so the investment is spread more widely than the traditional hubs in Massachusetts and New Jersey.

Several of the largest single sites are in states with little prior large-scale pharma manufacturing, including Lilly's $6B active ingredient plant in Huntsville, Alabama, and UCB's $2B biologics plant in Gwinnett County, Georgia, its first US manufacturing site.

The largest named site investments

CompanyLocationFocusAnnounced amountAnnounced
Eli LillyHouston, TexasSmall-molecule active ingredients, including orforglipron$6.5BSep 2025
Eli LillyHuntsville, AlabamaSmall-molecule and peptide active ingredientsMore than $6BDec 2025
Eli LillyGoochland County, VirginiaBioconjugates, antibody-drug conjugates, and antibodies$5BSep 2025
AstraZenecaAlbemarle County, VirginiaDrug substance for metabolic medicines and antibody-drug conjugates$4.5BJul and Oct 2025
Eli LillyLebanon, IndianaActive ingredients and genetic medicine$4.5B (additional)May 2026
Eli LillyFogelsville, PennsylvaniaInjectables and devicesMore than $3.5BJan 2026
MerckRahway, New JerseyResearch and clinical manufacturingMore than $3.5BOct 2025
MerckElkton, VirginiaSmall-molecule active ingredients and drug product$3BOct 2025
Bristol Myers SquibbHouston, TexasSmall molecules, biologics, and antibody-drug conjugatesAbout $2.3BAug 2026
BayerNew Albany, OhioDrug substance and drug product$2.2BOct 2026

What the sites will make

Active ingredients and obesity medicines account for much of the new capacity. Lilly's new sites in Texas ($6.5B) and Alabama (more than $6B) will produce small-molecule and peptide ingredients, including for orforglipron, and Genentech raised its Holly Springs, North Carolina investment for metabolic and obesity medicines from more than $700M to about $2B.

Biologics and newer modalities make up most of the rest. Merck's $1B site in Wilmington, Delaware will produce biologics including future US supply of Keytruda, AstraZeneca added antibody-drug conjugates to the scope of its $4.5B Virginia plant, and Novartis is adding radioligand therapy capacity across 5 sites in Florida, Texas, Indiana, New Jersey, and California.

Company-level commitments

CompanyUS commitmentPeriod
AbbVie$100B in R&D and capitalNext decade
MerckMore than $70B in manufacturing and R&DFrom 2025
PfizerAn additional $70B in R&D and capital projectsNext few years
Johnson & JohnsonMore than $55BThrough early 2029
Roche$50B5 years
AstraZeneca$50BBy 2030
Bristol Myers Squibb$40B5 years
Gilead$32B, of which $11B is newThrough 2030
GSK$30B5 years
Eli LillyMore than $50B since 2020, of which $23B was committed by 2024Since 2020
Novartis$23B5 years
SanofiAt least $20BThrough 2030

How policy shaped the announcements

The announcements followed the Commerce Department's Section 232 investigation into pharmaceutical imports, opened in April 2025, and the tariff proclamation signed on April 2, 2026, which set a 100% tariff on patented drugs, a 20% rate for companies with an approved US manufacturing plan, and no tariff until January 2029 for companies that also have a pricing agreement.

Companies tied many of their commitments to those pricing agreements, starting with Pfizer's additional $70B on September 30, 2025, and by September 2026 the White House counted 26 manufacturers with agreements covering 89% of the branded drug market.

Progress so far

Of the projects announced in 2025, 14 have broken ground and 5 are open or operating, including AstraZeneca's expanded Coppell, Texas plant and Novartis's radioligand therapy site in Carlsbad, California. Most of the other sites expect to start operating between 2027 and 2032, so the new capacity will arrive gradually over the rest of the decade.

Implications

The investments shift US capacity toward active ingredient production and obesity medicines first, and they spread it across 20 states. Many site amounts remain undisclosed, including Gilead's Foster City buildings and several Novartis and AstraZeneca sites, so the $66.1B figure understates total site-level spending.

Teams that monitor competitors' manufacturing and capacity investments often compare several intelligence platforms, and our guide to the best pharma competitive intelligence tools sets out the main options.

Methodology: The review covers US manufacturing and R&D sites with a named state and city announced between January 1, 2025 and November 10, 2026 by the 20 largest biopharma companies by revenue and other companies with a single US site of $1B or more, from company press releases and state economic development announcements. Puerto Rico projects, contract manufacturing agreements, and sites without a named location are excluded. Site totals use the latest company figure and the floor of "more than" amounts. Company-level commitments are as each company stated them, cover different periods, often include R&D, and overlap with the site amounts, and the about $600B total also includes Boehringer Ingelheim ($10B), Novo Nordisk ($10B, as reported by the White House), Regeneron ($9B), and CSL ($1.5B), with Lilly counted at $27B of new commitments.

Research your next biopharma question with Maven.